Display options
Cite
Naeshiro N, Aikata H, Hyogo H, et al. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2014;45(6):656-62doi: 10.1111/hepr.12400.
Naeshiro, N., Aikata, H., Hyogo, H., Kan, H., Fujino, H., Kobayashi, T., Fukuhara, T., Honda, Y., Nakahara, T., Ohno, A., Miyaki, D., Murakami, E., Kawaoka, T., Tsuge, M., Hiraga, N., Hiramatsu, A., Imamura, M., Kawakami, Y., Ochi, H., & Chayama, K. (2015). Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 45(6), 656-62. https://doi.org/10.1111/hepr.12400
Naeshiro, Noriaki, et al. "Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,6 (2015): 656-62. doi: https://doi.org/10.1111/hepr.12400
Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 02. PMID: 25088236.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 02.

Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Noriaki Naeshiro, Hiroshi Aikata, Hideyuki Hyogo, Hiromi Kan, Hatsue Fujino, Tomoki Kobayashi, Takayuki Fukuhara, Yohji Honda, Takashi Nakahara, Atsushi Ohno, Daisuke Miyaki, Eisuke Murakami, Tomokazu Kawaoka, Masataka Tsuge, Nobuhiko Hiraga, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki Chayama

Affiliations

  1. Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.

PMID: 25088236 DOI: 10.1111/hepr.12400

Abstract

AIM: To assess the efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis (PVT) in patients with liver cirrhosis.

METHODS: A consecutive 26 cirrhotic patients with PVT were enrolled in this retrospective cohort study. The etiologies of cirrhosis were hepatitis B virus-related, hepatitis C virus-related, alcoholic and cryptogenic in five, 14, three and four patients, respectively. Child-Pugh grade A, B and C was noted in 13, eight and five patients, respectively. Patients were treated with 2 weeks' administration of danaparoid sodium followed by the evaluation of PVT reduction and adverse events.

RESULTS: All patients experienced reduction of PVT through the treatment. The median volume of PVT before and after treatment was 2.40 cm(3) (range, 0.18-16.63) and 0.37 cm(3) (range, 0-5.74), respectively. The median reduction rate of PVT volume was 77.3% (range, 18-100%). According to the reduction rate, complete reduction (CR), partial reduction (PR, ≥50%) and stable disease (SD, <50%) were observed in four (15%), 16 (62%) and six patients (23%), respectively. The median volume of PVT before treatment was significantly different between CR + PR and SD (2.09 vs 4.35 cm(3) , P = 0.045). No severe adverse events such as bleeding symptoms (e.g. gastrointestinal bleeding and cerebral hemorrhage) and thrombocytopenia were encountered.

CONCLUSION: Danaparoid sodium for the treatment of PVT in patients with liver cirrhosis was safe and effective. Therefore, anticoagulation therapy with danaparoid sodium could have potential as one of the treatment options in PVT accompanied by cirrhosis.

© 2014 The Japan Society of Hepatology.

Keywords: anticoagulation; danaparoid sodium; liver cirrhosis; portal vein thrombosis

Publication Types